Business Context and Reporting Period
This Form 8-K is a current report filed by AlloVir, Inc. (not Kalaris Therapeutics, Inc.) on July 22, 2021. The filing addresses a specific corporate governance event regarding the former Chief Executive Officer, David Hallal, who resigned effective May 17, 2021.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to a specific compensatory arrangement:
- Consulting Fee: $100,000 payable to David Hallal for services under a new agreement.
Material Changes
The material change reported is the execution of a Consulting Agreement between AlloVir, Inc. and David Hallal, effective July 22, 2021. This agreement formalizes Mr. Hallal's role post-resignation, extending his engagement until May 17, 2022.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of general business risks. The primary contingency noted is the obligation to pay the $100,000 consulting fee as defined in the agreement filed as Exhibit 10.1.
Investor Verification Checklist
- Verify the company name is AlloVir, Inc. (Ticker: ALVR), not Kalaris Therapeutics, Inc.
- Confirm the terms of the Consulting Agreement (Exhibit 10.1) regarding the $100,000 fee and service scope.
- Review the prior Form 8-K filed on March 17, 2021, for details on Mr. Hallal's original resignation.
- Note that this filing does not contain updated financial performance data.